#USA #Class Action #Los Angeles #Securities Law #Ultragenyx

Ultragenyx Pharmaceutical Inc. Faces Class Action Lawsuit

On February 23, 2026, the DJS Law Group announced a class action lawsuit against Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company specializing in gene therapies. Investors who purchased shares during a specified class period, from August 3, 2023, to December 26, 2025, are especially encouraged to engage with the law firm regarding their rights and potential recovery options.

Background on the Allegations

The lawsuit claims that Ultragenyx provided false and misleading information to the market, contributing to overly optimistic perceptions concerning its drug candidate's performance in a critical Phase III trial. Despite the company's claims of positive outcomes, the reports suggest that the trial did not meet essential statistical endpoints, leading to significant concerns about the veracity of Ultragenyx's public statements.

Investors assert that they were misled by these statements, which potentially inflated the stock price and caused subsequent financial losses after the truth emerged. This discrepancy raises serious questions not only about the company's transparency but also about the potential implications for future investors.

Importance of Engaging with DJS Law Group

The DJS Law Group is known for its commitment to maximizing investor returns, particularly in cases involving securities actions. They focus on providing robust representation and advocating vigorously for shareholder rights. Their specialization extends to various areas, including corporate governance litigation and joint ventures, making them a formidable ally in the fight for investor recovery.

Eligible shareholders are encouraged to reach out to DJS Law Group, even if they do not wish to pursue lead plaintiff status, to discuss their experiences and possible entitlements. The firm emphasizes that participation in the recovery process does not necessitate becoming a lead plaintiff, allowing broader opportunities for affected individuals to reclaim their losses.

Class Period and Key Deadlines

The class action defines its relevant period as being between August 3, 2023, and December 26, 2025. Prospective claimants should be aware that the deadline to file claims is set for April 6, 2026. It’s crucial for shareholders to act quickly to ensure they do not miss out on their opportunities for potential recovery.

Summary

The allegations levied against Ultragenyx Pharmaceutical Inc. underscore the importance of transparency and integrity in corporate communications, especially in sectors as sensitive as pharmaceuticals. Investors must remain vigilant and informed to protect their interests. The DJS Law Group is on standby to assist shareholders in navigating this complex situation and to facilitate potential recovery from what many view as misleading corporate practices.

For further inquiries, shareholders are directed to contact David J. Schwartz at the DJS Law Group. The dedicated team is prepared to offer guidance and support as affected investors take the necessary steps toward justice.

• ---